IDS and mucopolysaccharidosis type 2: Overall, although somatic improvements were observed with IV idursulfase administration in patients with neuronopathic MPS II (mostly in terms of uGAG levels and liver volume), these were generally not as pronounced as those in patients with non-neuronopathic MPS II.